EW Edwards: EV/EBITDA Multiple
Edwards Lifesciences is implementing eco-design packaging and transitioning to renewable energy. The EV/EBITDA multiple trend on the GURU.Markets terminal linear chart shows that the parameter has stabilized at 27.27. Edwards Lifesciences generates revenue from hemodynamic monitoring systems and valves, seeking niche dominance through large-scale R&D investments to create technological barriers.
EW (edwards.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Edwards Lifesciences|EW - Long-Term Liabilities to Capital|Short-Term Debt to Capital Edwards Lifesciences Corporation|EW - Company Aggregate Debt|Debts to Book Capitalization Edwards Lifesciences Inc.|EW - Long-Term Debt Volume|Company Short-Term Debts Edwards Lifesciences|Quick Ratio edwards.com
- net income and valuation multiples indicators:
EW - Net Profit|Expected Profit Edwards Lifesciences|EW - Price to Earnings Ratio|Projected Price to Earnings Edwards Lifesciences|EW - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Edwards Lifesciences Inc.|EW - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Edwards Lifesciences|EW - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months edwards.com|EW - Earnings growth in current year|Earnings growth forecast for next year Edwards Lifesciences
Fundamental company valuation:Edwards Lifesciences Corp EW
The scaling of TAVR procedures and the launch of the EVOQUE system are generating a steady operating cash flow for Edwards Lifesciences (EW). This metric compares the total enterprise value to earnings before depreciation and amortization, ignoring the impact of tax policy and debt structure. Through this ratio, an investor determines the payback period of assets and the issuer's margin of safety. By analyzing the dynamic EV/EBITDA ratio of the company, one can identify overvaluation or the search for a market bottom.
Analysis of competing companies
EV/EBITDA Multiple BSX (Boston Scientific Inc)|ResMed Corporation (RMD) - Company Value to EBITDA|Insulet Corporation - EV/EBITDA Multiple|ZBH (Zimmer Biomet Holdings Inc) - Enterprise Value to Operating Income Before Depreciation|COO (CooperCompanies) - Enterprise Value to EBITDA Ratio|Invisalign - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Globus Medical Corp|Enterprise Value to EBITDA Ratio transmedics.com (TMDX)|EV/EBITDA Multiple ATEC|AORT - Company Value to EBITDA|EV/EBITDA Multiple ENOV (Enovis)|IART: Enterprise Value to Operating Income Before Depreciation|Motiva - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio iLet Bionic Pancreas BBNX|IRMD: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio embecta.com|TNDM (Tandem Diabetes Care, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple AxoGen Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SI-BONE Corp (SIBN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OFIX (Orthofix Corp)|Bioventus Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KIDS|Treace Medical Concepts, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Blade Air Mobility|Carlsmed Corp (CARL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple RxSight Ophthalmic RXST|Enterprise Value to EBITDA Ratio CLPT|EV/EBITDA Multiple stereotaxis.com|EV/EBITDA Multiple STIM|Total Company Value to Operating Income Before Depreciation Ratio Sight Sciences Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Orchestra BioMed OBIO|ANIK (Anika Therapeutics Inc.) - Company Value to Operating Income Before Depreciation Ratio|NSPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Jin Medical International (ZJYL) - Enterprise Value to EBITDA Ratio|VANI: EV/EBITDA Multiple|Company Value to EBITDA Xtant Medical (XTNT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Corp|Enterprise Value to Operating Income Before Depreciation MODD (Modular Med)|Enterprise Value to EBITDA Ratio MYO (Myomo, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio COCH|EV/EBITDA Multiple VVOS (Vivos Therapeutics, Inc.)|enVVeno Medical Corporation (NVNO) - Company Value to EBITDA|SINTX Technologies - EV/EBITDA Multiple|TNON (Tenon Medical Inc) - Enterprise Value to Operating Income Before Depreciation|LFWD (ReWalk Robotics Ltd.) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Autonomix Medical|IVF (INVO Fertility) - EV/EBITDA Multiple|EV/EBITDA Multiple Bone Biologics Corp.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axonics Modulation Technologies (AXNX)|BIOL (Biolase Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple DYNT (Dynatronics)|FNA: Enterprise Value to Operating Income Before Depreciation|INVO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
